Loxo Oncology Announces FDA Clearance of Investigational New Drug (IND) Application for Next-Generation TRK Inhibitor, LOXO-195

STAMFORD, Conn., May 30, 2017 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, today announced that the United...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials